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Cofactor Dynamics and Sufficiency in Estrogen
Receptor–Regulated Transcription
ciated factor, pCAF (Blanco et al., 1998). Coactivators
such as CBP, p300, pCAF, and possibly SRC1 and AIB1
possess intrinsic histone acetyltransferase (HAT) activi-
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Dana-Farber Cancer Institute and ties capable of modifying the chromatin organization of
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in ER transactivation raises the question of functionalHarvard Medical School
Boston, Massachusetts 02115 redundancy. In addition a distinct multiprotein complex
first found to be involved in thyroid hormone receptor†Division of Endocrinology, Diabetes,
and Metabolism (TR) and vitamin D receptor (VDR) signaling (Fondell et
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The Penn Diabetes Center recently in ER action through an interaction with its PBP/
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Much of our current knowledge regarding the involve-
ment of these proteins in nuclear receptor signaling is
based on their ability to bind liganded-receptors in vitroSummary
and enhance transcriptional activation in transfection
experiments. Although the participation of so many pro-Many cofactors bind the hormone-activated estrogen
receptor (ER), yet the specific regulators of endoge- tein factors in ER-mediated gene transactivation un-
doubtedly reflects the complexity of the transcription innous ER-mediated gene transcription are unknown.
Using chromatin immunoprecipitation (ChIP), we find eukaryotes, it also raises the question of which if any
of these coactivators are necessary and/or sufficient forthat ER and a number of coactivators rapidly associate
with estrogen responsive promoters following estro- the transcriptional activation of ER in vivo. In addition,
the transcriptional dynamics of ER action are also notgen treatment in a cyclic fashion that is not predicted
by current models of hormone activation. Cycles of well understood. The traditional view that activators
such as ER bind to a response element in the promoterER complex assembly are followed by transcription.
In contrast, the anti-estrogen tamoxifen (TAM) recruits of a target gene and remain associated for as long as
the stimulus is present (Hahn, 1998; Berk, 1999) is incon-corepressors but not coactivators. Using a genetic
approach, we show that recruitment of the p160 class sistent with a recent report that the association of ER
and AIB1 is a transient process that is disrupted byof coactivators is sufficient for gene activation and for
the growth stimulatory actions of estrogen in breast acetylation of AIB1 by CBP/p300 (Chen et al., 1999).
This raises the question of whether the ER complexcancer supporting a model in which ER cofactors play
unique roles in estrogen signaling. might cycle on and off the target gene promoters.
We have addressed these critical questions under
biologically relevant conditions through the study of en-Introduction
dogenous ERa and cofactors in breast cancer cells.
Using chromatin immunoprecipitation (ChIP) we findEstrogen plays an important role both in reproductive
physiology and in numerous human disease states, in- that in response to estrogen native ER transcription
complexes are stimulated to assemble on target pro-cluding breast and endometrial cancers, cardiovascular
disease, osteoporosis, and Alzheimer’s disease. The moters in a cyclic fashion. These experiments demon-
strate differential roles for the various coregulators inbiological actions of estrogen are mediated by the prod-
ucts of two genes within the nuclear receptor family, the assembly of ER transcription complexes in vivo. In
addition we demonstrate that TAM-bound ER recruitsestrogen receptor (ER) a and b. Current models of ER
action suggest that it modulates the rate of transcription corepressors but not coactivators to target promoters
suggesting that the cellular responses to a selective ERinitiation through interactions with the basal transcrip-
tion machinery and through alterations in the state of modulator (SERM) such as TAM may reflect the balance
between coactivators and corepressors present in dif-chromatin organization at the promoter of target genes
via the recruitment of a variety of coactivators. ferent cells. Finally, using a p160 coactivator that binds
ER with reversed ligand specificity, we show that recruit-The assortment of coactivator proteins implicated in
estrogen signaling includes three distinct but related ment of this class of coactivator is sufficient for gene
activation as well as estrogen-dependent cell cycle pro-p160 family members, SRC-1, TIF2 or GRIP-1, and AIB1
(also referred to as ACTR, RAC3, pCIP, or NCoA-3) gression.
(Onate et al., 1995; Anzick et al., 1997; Chen et al., 1997;
Hong et al., 1997; Li et al., 1997; Torchia et al., 1997) Results
and the histone acetylases CBP, p300 (Chakravarti et
al., 1996; Hanstein et al., 1996) and the p300/CBP-asso- Estrogen Induces Occupancy of Estrogen Target
Gene Promoters by ERa and p160 Coactivators
To investigate the assembly of the ER transcription com-§ To whom correspondence should be addressed (e-mail: myles_
brown@dfci.harvard.edu). plex, we first examined the recruitment of ERa and p160
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immunoprecipitates was analyzed by semiquantitative
PCR using specific pairs of primers spanning the estro-
gen responsive regions in the three promoters. As
shown in Figures 1A, treatment with E2 induced a dra-
matic increase in the occupancy by both ERa and AIB1
of the CATD, pS2 and c-Myc gene promoters. Similar
promoter occupancy by the other p160 family members
SRC-1 and GRIP1 was also observed (data not shown).
As expected, given the z500 bp to z2000 bp size of
the DNA fragments produced by sonication in these
experiments, PCR analysis did not detect any significant
increase in ERa or AIB1 occupancy of a region z3 kb
upstream of the CATD promoter (Figure 1B). In addition,
treatment of MCF-7 cells under the same conditions
with 1,25-(OH)2D3 (VD3) failed to induce any increase in
ERa or AIB1 association with these promoters (Figure
1C), although VD3 treatment did result in an increased
occupancy of the VD3 receptor (VDR) on the promoters
of VD3 responsive p21 (Liu et al., 1996; Verlinden et al.,
1998) and fibronectin (Polly et al., 1996) genes (Figure 1D).
Dynamics of ER Transcription Complex Assembly
Having shown that estrogen is able to induce occupancy
of responsive promoters by ERa and AIB1, we sought
to understand the precise order and timing of complex
assembly using ChIP. Strikingly, ERa is recruited to the
CATD promoter within 15 min following the addition of
E2 (Figure 2A). ERa promoter occupancy peaks at 30–45
min and returns to baseline by 75 min. To further validate
these findings, we designed a highly quantitative ChIP
assay using real-time PCR and an ABI PRISM 7700 Se-
quence Detector (Perkin-Elmer). Quantitative ChIP was
performed to determine the relative levels of CATD pro-
Figure 1. The Recruitment of ERa and AIB1 to the Promoters of moter occupancy by ERa following treatment of MCF-7
Estrogen-Responsive Genes cells with E2. The measured level of CATD promoter
(A) Soluble chromatin was prepared from MCF-7 cells treated with occupied by ERa increased z50-fold within 15 min fol-
E2 for 45 min and immunoprecipitated (IP) with antibodies against
lowing the addition of E2. Maximal induction of promoterERa (aERa) or against AIB1 (aAIB1). The final DNA extractions were
occupancy of greater than 100-fold was detected at 30amplified using pairs of primers that cover the regions of cathepsin
min and this returned almost to baseline at later times.D, pS2 and c-Myc gene promoters as indicated. (B) The distal region
of the cathepsin D gene promoter was examined for the presence Thus the differences observed by ChIP in Figure 2A
of ERa and AIB1. (C) MCF-7 cells were treated with 1,25-(OH)2D3 reflect very significant quantitative changes in promoter
(VD3) for 45 min and the cathepsin D, pS2, and c-Myc gene promoters occupancy and confirm that ERa cycles onto and off of
were examined for the occupancy by ERa or AIB1 using the same
the CATD promoter in response to E2. In order to ruleantibodies and primers as in (A). (D) MCF-7 cells were treated with
out epitope masking as an alternate explanation for the1,25-(OH)2D3 (VD3) for 45 min and the occupancy of the vitamin D
apparent cycling of ERa, we used multiple monoclonalreceptor (VDR) on the p21 and fibronectin gene promoters was
examined. antibodies directed toward different ERa epitopes in the
ChIP assay. Three different monoclonal antibodies gave
almost identical patterns of ERa association with the
CATD promoter suggesting that epitope masking is ancoactivators to the promoters of endogenous estrogen-
responsive target genes following estrogen treatment. unlikely explanation for the observed cycling (data not
shown).The estrogen-dependent human breast cancer cell line
MCF-7 was used for these studies as there are several We next sought to determine the participation and
timing of association of the various coactivator proteinswell-characterized estrogen target genes in these cells.
Three estrogen target genes, cathepsin D (CATD), pS2, in the formation of the ERa transcription complex, and
the relationship of this to the state of histone acetylationand c-Myc (Dubik and Shiu, 1992; Augereau et al., 1994;
Giamarchi et al., 1999) were examined. MCF-7 cells were and the onset of gene transcription. As was observed
for ERa, the coactivators AIB1, PBP, and p300 all rapidlygrown in the absence of estrogen for at least three days
followed by either no treatment or treatment with satu- and transiently associate with the CATD promoter as
significant CATD promoter occupancy is observedrating levels of 17b-estradiol (E2) for 45 min. The status
of the endogenous transcription complexes present on within 15–30 min following the addition of E2. Concur-
rent with this first wave of factor association, histonesthe estrogen responsive regions of these promoters was
determined using chromatin immunoprecipitation (ChIP). associated with the CATD promoter are acetylated. This
is closely followed by the association of RNA pol II. CBPThe presence of the specific promoters in the chromatin
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beginning about 100 min following estrogen stimulation
differs somewhat from the first. While ERa, AIB1, PBP,
CBP, pCAF all assemble in the same order and with the
same timing as in the first cycle, p300 is not detected
in the second cycle of complex assembly. Interestingly,
while a second increase in the level of acetylated his-
tones associated with the CATD promoter is detected
during the second cycle, this is from a baseline level that
remains elevated between the first and second cycle of
complex assembly.
In order to confirm that the repeated cycling of the
ERa complex was not unique to the CATD promoter in
MCF-7 cells, we examined in detail the association of
ERa and AIB1 with the pS2 promoter (Figure 2B). As
was seen on the CATD promoter, both ERa and AIB1
repeatedly cycle onto and off of the pS2 promoter with
very similar dynamics. This suggests that the cyclic na-
ture of ERa complex assembly may be a general prop-
erty of ERa-regulated genes. In addition, to determine
whether the cyclic nature of the recruitment of the ER
transcription complex to the CATD promoter is re-
stricted to MCF-7 breast cancer cells, similar time
courses were performed in ECC-1 endometrial cancer
cells. Like MCF-7, ECC-1 cells express ERa and are E2
responsive for CATD expression and growth (Castro-
Rivera et al., 1999). A very similar pattern of ERa and
AIB1 recruitment to the CATD promoter was seen in
ECC-1 as was seen in MCF-7 (data not shown). Whether
the details of the factors involved and the timing of their
assembly differ in a promoter- and/or cell type–specific
manner is an intriguing possibility that remains to be
determined.
To assess when the ERa transcription complex be-
comes competent for gene activation, we examined
whether the repeated cycles of complex assembly are
followed by transcription. Nuclear run-on assays were
performed on the c-Myc, pS2, and CATD genes follow-
ing estrogen stimulation of MCF-7 cells (Figure 2C). Sig-
nificant transcription is evident after 45 min of estrogen
stimulation. This follows the assembly of ERa, PBP,Figure 2. The Dynamics of ERa Transcription Complex Assembly
AIB1, p300, and pol II on the promoter and precedes(A) Occupancy of the cathepsin D (CATD) promoter by ERa, different
the association of CBP and pCAF. Interestingly, as iscoactivators, acetylated histones (AcH) and RNA polymerase II (pol
seen with assembly of ERa and its associated cofactorsII) at different times as measured by ChIP. (B) Occupancy of the
pS2 promoter by ERa and AIB1 as measured by ChIP. (C) Nuclear on the promoter, transcription is also cyclic. These re-
run-on analysis of the expression of c-Myc, pS2, CATD, and b-actin sults confirm that the cyclic assembly of the ERa com-
mRNA in MCF-7 cells treated with E2 for various times. (D) ChIP plex on the promoter is followed by cycles of tran-
Re-IP to examine whether the ERa-PBP complex and ERa-AIB1 scription.complex are assembled on the same promoters. Soluble chromatin
Additionally, the time course of coactivator recruit-was prepared from MCF-7 cells treated with E2 for 40 min and
ment reveals important aspects of the function of twodivided into two aliquots. One aliquot was first immunoprecipitated
distinct coactivator complexes. PBP, the protein thatwith antibodies against AIB1 (10 IP). The supernatant was collected
and reimmunoprecipitated with antibodies against PBP (Superna- anchors the DRIP/TRAP complex to ERa and to other
tant Re-IP). The other aliquot was first immunoprecipitated with nuclear receptors (Rachez et al., 1998, 1999, 2000; Bura-
antibodies against PBP (10 IP) followed by reimmunoprecipitation kov et al., 2000) is recruited to the CATD promoter at
with antibodies against AIB1. Similar reciprocal Re-IPs were also
the same time as ERa and AIB1. This result rules out aperformed on complexes eluted from the 10 IPs (Bound Re-IP).
sequential model and supports either a combinatorial
model in which the PBP and AIB1 containing complexes
and pCAF also become transiently associated with the act simultaneously on the very same CATD promoters
same region of the CATD promoter but only beginning or a parallel model in which the two complexes are being
at about 45 min following the onset of E2 stimulation. recruited to distinct subsets of CATD promoters on dif-
This is a time when association of the first wave of ferent alleles or in different cells. In order to test whether
factors is already falling suggesting that CBP and pCAF a combinatorial or a parallel model applies, we per-
function at a distinct step in the process of ERa-medi- formed a serial ChIP experiment (Figure 2D). For this we
ated activation. divided the soluble chromatin derived from E2-treated or
untreated cells into two aliquots. One was immunopre-Notably, the second cycle of promoter occupancy
Cell
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Figure 4. Promoter Occupancy by ERa and Cofactors Induced by
Tamoxifen (TAM)
(A) ChIP demonstrates the promoter occupancy by ERa and the
indicated cofactors on the CATD (left panel) and pS2 (right panel)
promoters from MCF-7 cells treated with TAM.
support a model in which AIB1 and PBP act in a combi-
natorial fashion on the same ERa responsive promoter.
Phosphorylation of pol II Is Required
for ER Complex Cycling
Our data show that the association of ERa and the other
components of the transcription initiation complex with
the promoter is cyclical. This raises the question of what
events regulate the release of the complex from the
promoter. We first examined whether the overall cellular
levels of the factors change over the time course ofFigure 3. Mechanism of ERa Transcription Complex Disassembly
estrogen stimulation. The levels of ERa and the other(A) Protein levels of the components of the ERa transcription com-
factors do not fluctuate significantly over the first hourplex in MCF-7 cells at different times following estrogen treatment
measured by Western blotting. (B) Recruitment patterns of ERa, of E2 treatment during which time they have cycled onto
AIB1, RNA polymerase II (pol II) and phosphorylated RNA polymer- and off of the CATD promoter and stable levels are
ase II (pol IIo) on the cathepsin D promoter in MCF-7 cells treated present for as long as 6 hr (Figure 3A).
with a-amanitin (left panel) or DRB (right panel) followed by E2 for
To address whether release from the promoter occursdifferent times. (C) Western blot analysis of the phosphorylation
at a specific step during transcription initiation, two in-status of RNA polymerase II after treatment with a-amanitin (left
hibitors of transcription, a-amanitin and 5,6-dichloro-1-panel) or DRB (right panel) followed by E2 for various times. Both
underphosphorylated (IIa) and hyperphosphorylated (IIo) forms of b-D-ribofuranosylbenzimidazole (DRB) were used. MCF-7
the large subunit of RNA polymerase II are shown. (D) Inhibition of cells were treated with either 10 mg/ml of a-amanitin or
transcription by a-amanitin (left panel) and DRB (right panel) was 50 mM of DRB for 1 hr before the addition of E2, and
confirmed by Northern blotting in MCF-7 cells for the expression of
CATD promoter occupancy was determined by ChIP forthe CATD mRNA. b-actin serves as a loading control.
ERa, AIB1, and both total RNA pol II and its hyperphos-
phorylated IIo form (Figure 3B).
a-Amanitin is able to bind to the large subunit of RNAcipitated with AIB1 antibodies followed by release of
the immune complexes and reimmunoprecipitated (Re- pol II (Kedinger et al., 1970; Lindell et al., 1970) and
block the incorporation of new nucleotides into the na-IP) with PBP antibodies. The other was first immunopre-
cipitated with PBP antibodies followed by release and scent RNA chain (de Mercoyrol et al., 1989). Interestingly
a-amanitin had no obvious effect on the pattern of CATDRe-IP with AIB1 antibodies. The same Re-IP was also
performed on the unbound supernatant fractions from promoter occupancy by ERa, AIB1, and RNA pol II (Fig-
ure 3B, left panel) or the generation of the phosphory-the primary immunoprecipitation. While both AIB1 anti-
bodies and PBP antibodies were able to immunoprecipi- lated IIo form of pol II (Figures 3B and 3C, left panel)
though CATD transcription was significantly inhibitedtate the CATD promoter after cells were treated with E2
(Figure 2D), subsequent supernatant Re-IPs with either by a-amanitin (Figure 3D, left panel). Thus, the assembly
and subsequent release of the ERa transcription com-PBP antibodies or AIB1 antibodies were unable to do
so. On the other hand, subsequent Re-IPs of the eluted plex from the CATD promoter does not depend on the
incorporation of nucleotides into the nascent RNA tran-primary immunoprecipitates were able to bind the CATD
promoter (“bound” in Figure 2D). These experiments script.
Assembly Dynamics of ER Complexes
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Figure 5. Central Role for p160 Proteins in
the Assembly of the ERa Transcription
Complex
(A) Diagram of the structure of subGRIP1 and
subPBP. (B) Interaction of in vitro transcribed
and translated GRIP1, PBP, subGRIP1, and
subPBP with glutathione S-transferase (GST)
or a GST fusion of helix 12 deleted RXR (GST-
RXRDH12) was assayed by GST pulldown in
the absence of ligand. (C) ChIP (left panel)
and reporter (right panel) assays were per-
formed on MCF-7 cells transfected with the
indicated expression plasmids and treated
with TAM (upper panel) or E2 (lower panel).
The occupancy of the CATD promoter by
ERa, GRIP1, CBP, PBP, and acetylated his-
tone (AcH) was examined. (D) Western blot-
ting analysis of protein expression in MCF-7
cells transfected with GRIP1 (lane 2) or sub-
GRIP1 (lane 3), or transfected with PBP (lane
5) or subPBP (lane 6). Lane 1 and lane 4 are
vector transfection controls.
DRB acts to block transcription by inhibiting CDK7 lation of the C-terminal domain contributes to the initia-
tion of transcription and elongation of the primary tran-(Yankulov et al., 1995) and CDK9 (Marshall et al., 1996),
two kinases responsible for phosphorylating the RNA script (Corden and Patturajan, 1997; Bentley, 1998).
Taken together with the ability of the ERa transcriptionpol II large subunit C-terminal domain. In contrast to
what we found with a-amanitin, DRB treatment led to complex to be released from the promoter in the pres-
ence of a-amanitin, we conclude that promoter releasethe stabilization of ERa, AIB1, and RNA pol II on the
CATD promoter for several hours (Figure 3B, right panel). occurs subsequent to RNA pol II C-terminal domain
phosphorylation and prior to or concurrent with tran-As expected DRB also effectively blocked CATD tran-
scription (Figure 3D, right panel) as well as the phosphor- scription initiation.
ylation of pol II (Figures 3B and 3C, right panel). These
results suggest that the release of the ERa transcription Tamoxifen Induces the Formation
of an ER-Corepressor Complexcomplex from the promoter requires the phosphoryla-
tion of the RNA pol II large subunit and are consistent Tamoxifen (TAM) competes with E2 for ERa binding and
induces a conformational change in which the recruit-with other data showing that the activity of RNA poly-
merase II is regulated by multisite phosphorylation on ment of p160 coactivators is blocked (Halachmi et al.,
1994; Brzozowski et al., 1997). In addition, while it func-its C-terminal domain. Underphosphorylated RNA pol II
C-terminal domain is believed to mediate multiple pro- tions as an antagonist in breast cancer cells such as
MCF-7, in other tissues and on certain promoters TAMtein–protein interactions involved in the assembly of the
preinitiation complex while the subsequent phosphory- acts as a partial ERa agonist. This property has led TAM
Cell
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to be viewed as the prototypical selective ER modulator
or SERM. To investigate further the mechanisms under-
lying the activity of TAM-ERa, we examined the recruit-
ment of coactivators or corepressors in MCF-7 cells
after treatment with TAM (Figure 4). As was observed
with E2, TAM treatment induced ERa occupancy of the
CATD (Figure 4, left panel) and pS2 promoters (Figure
4, right panel). As expected, the TAM-ERa complex did
not recruit p160 coactivators such as AIB1 nor CBP nor
p300. In marked contrast, when we examined promoter
occupancy by corepressors, we detected the recruit-
ment of the nuclear receptor corepressors N-CoR and Figure 6. Induction of Cell Proliferation in MCF-7 Cells Expressing
SMRT. These data show that in addition to inducing a subGRIP1
conformational change in ERa that blocks coactivator MCF-7 cells were grown in DMEM supplemented with 10% char-
recruitment, TAM is able to induce the recruitment of coal-dextran-stripped fetal bovine serum for 24 hr and were cotrans-
fected with a GFP expression plasmid together with either a GRIP1ERa and an associated corepressor complex to the pro-
or a subGRIP1 expression plasmid. Forty-eight hours after transfec-moter, suggesting TAM-ERa may be actively involved
tion, cells were treated with 100 nM E2 or 5 mM TAM or untreatedin gene repression. This also suggests that the ratio of
for another 16 hr. Cells were then collected and analyzed by flow
agonism to antagonism seen with SERMs such as TAM cytometry. The numbers indicate the increase in the percentage of
may be influenced by the levels or activity of the corepres- GFP-positive cells that are in the S/G2/M phases of the cell cycle
sor complex. after 16 hr treatment with E2 or TAM.
p160 Proteins Play a Central Role in the Assembly
and Activity of the ER Transcription Complex trast, after introduction of subGRIP1 into MCF-7 cells,
TAM was able to induce the recruitment of not only ERa,PBP and the p160 coactivators utilize similar NR boxes
that specifically recognize the agonist-bound conforma- but also GRIP1 and CBP (Figure 5C, upper left panel).
Remarkably, subGRIP1 transfection led to histone acet-tion of ERa. The NR box is characterized by an LXXLL
sequence flanked with a short stretch of amino- and ylation in response to TAM, suggesting that subGRIP1
was sufficient to induce an activated chromatin templatecarboxyl-terminal amino acids and is both necessary
and sufficient for ligand-dependent interactions of p160 on the CATD promoter. Transcriptional activation was
confirmed by cotransfection of subGRIP1 with an estro-proteins and PBP with AF2 domains of nuclear receptors
(Heery et al., 1997; Ding et al., 1998). Analogously, the gen-responsive luciferase reporter (Figure 5C, right
panel). Importantly PBP was not recruited by TAM-ERatwo interaction domains of the nuclear receptor core-
pressors have been found to contain a conserved se- even in the presence of subGRIP1, suggesting that PBP
recruitment is not a necessary component of an activequence referred to as the CoRNR box (Hu and Lazar,
1999) or as an LXXI/HIXXXI/L helix that recognizes the ERa transcription complex.
To further assess the role of PBP in ERa-mediatedunliganded and repression competent form of thyroid
and retinoid receptors (Nagy et al., 1999; Perissi et al., gene activation, MCF-7 cells were transfected with ei-
ther wild-type PBP or CoRNR box-substituted PBP,1999). It has been suggested that the nuclear receptor
AF-2 helix has evolved to discriminate between the NR subPBP, and treated with TAM. As expected transfec-
tion of wild-type PBP did not facilitate the recruitmentbox LXXLL helix in coactivators and the CoRNR box
helix in the N-CoR/SMRT corepressors, permitting the of PBP, GRIP1, or CBP in response to TAM. Surprisingly
however, transfection of subPBP gave the same resultsligand-dependent switch of nuclear receptor activity. In
the case of ERa, this switch may be operated by agonist suggesting that substitution of the CoRNR box for the
NR box in PBP was not sufficient to promote its recruit-versus antagonist binding. In order to define the roles
of p160 proteins and PBP in the assembly and activities ment by TAM-bound ERa nor to allow gene activation
(Figure 5C, top panels), even though in control experi-of the ER transcription complex, we utilized chimeric
coactivator/corepressor proteins in which the three NR ments PBP recruitment and gene activation were ob-
served in both PBP and subPBP-transfected cellsboxes in GRIP1 and the two NR boxes in PBP had been
replaced by CoRNR boxes (Figure 5A). These CoRNR treated with E2 (Figure 5C, lower panels). Interestingly,
when both subGRIP1 and subPBP were introduced intobox substituted cofactors termed subGRIP and subPBP
are recruited to the unliganded and helix 12 deleted form cells, PBP was recruited to the ERa complex by TAM and
the addition of subPBP increased the level of activationof RXR in vitro while the wild-type proteins are not,
confirming their reversed specificity (Figure 5B). compared to that seen with subGRIP1 alone (Figure 5C,
top panels). These differences were not due to differ-The substituted cofactors were expressed in MCF-7
cells either separately or together, and promoter occu- ences in protein expression as measured by Western
blotting (Figure 5D). Taken together these results sug-pancy after treatment with E2 or TAM was assessed by
ChIP. When wild-type GRIP1 was expressed in MCF-7 gest that while substitution of the CoRNR box for the
NR box is sufficient for recruitment of p160 coactivatorscells, as expected, only ERa was recruited to the CATD
promoter in response to TAM (Figure 5C, upper left and ERa-mediated gene activation, the recruitment of
PBP to the ERa complex requires both an interactionpanel). As control, when these cells were treated with
E2, the recruitment of ERa, GRIP1, CBP, and PBP was with ERa and the presence of a p160 factor.
To determine whether the sufficiency of p160 actionobserved (Figure 5C, lower left panel). In marked con-
Assembly Dynamics of ER Complexes
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Figure 7. Cyclic Model of ER Transcription
Complex Assembly
The sequential formation of complexes lead-
ing to the activation of gene expression by
agonists such as estradiol. See text for de-
tails.
for gene activation extends to a physiologically relevant proteins for promoter binding can also be determined
using ChIP. Using ChIP, we found that p160 coactiva-response in breast cancer cells, we examined the effects
of TAM on cell cycle progression of MCF-7 cells ex- tors, CBP, p300, pCAF, and PBP are recruited in a spe-
cific order to the ER transcription complex after estrogenpressing subGRIP1. Estrogen is normally required for
G1/S transition of MCF-7 cells and estrogen deprivation stimulation in MCF-7 breast cancer cells.
Interestingly, the ER transcription complex appearsleads to a significant G1 arrest. We cotransfected estro-
gen-deprived MCF-7 cells with GRIP1 or subGRIP1 to- to repeatedly cycle onto and off of target promoters in
the presence of continuous stimulation by estrogen. Thegether with a green fluorescent protein (GFP) expression
construct. Cells then were treated with E2 or TAM and regular cycling of the ERa transcription complex may
represent a mechanism that favors continuous samplingthe cell cycle profile of the GFP-expressing population
was determined by flow cytometry (Figure 6). In E2- of the external milieu. Cycling may be regulated in part
by covalent modification of coregulators (Chen et al.,deprived MCF-7 cells expressing either wild-type GRIP1
or subGRIP1, z85% of the GFP-expressing cells were 1999; Font De Mora and Brown, 2000; Rowan et al.,
2000). In addition our inhibitor studies suggest that thearrested in the G0/G1 phase of the cell cycle. E2 addition
for 16 hr was able to release z15% of the GFP-express- cycling of the ERa complex off the promoter depends
on the phosphorylation of the C-terminal domain of theing cells into cell cycle with the G0/G1 fraction changing
from z85% to z70%. Treatment of wild-type GRIP1- large subunit of RNA pol II. Factors that alter the phos-
phorylation of RNA pol II might affect the respon-expressing cells with TAM for 16 hr had no effect on
the cell cycle profile with z85% of cells remaining in siveness of ERa-dependent promoters by interfering
with the cycling of ERa complex.G0/G1. In marked contrast, in cells expressing subGRIP1,
TAM treatment was able to effect the release of z11% We confirmed that TAM induces the recruitment of
ERa to responsive promoters. We did not observe re-of the cells into the cell cycle. These results indicate
that the recruitment by ERa of a p160 coactivator is cruitment of coactivators in response to TAM in MCF-7
cells, where TAM is a full antagonist. Consistent with insufficient to exert the cell proliferating properties of es-
trogen in breast cancer. vitro studies (Jackson et al., 1997; Smith et al., 1997;
Lavinsky et al., 1998), TAM-bound ERa did recruit nu-
clear receptor corepressors N-CoR and SMRT to theDiscussion
promoters as well. Preliminary data suggests that TAM-
ERa actively represses transcription of genes to whichDynamics of ER Transcription Complex Assembly
Genetic and biochemical studies over the past two de- it recruits these corepressors (data not shown).
cades have revealed that the process of gene activation
in eukaryotic cells is extremely complicated. Chromatin Functional Specificity and Sufficiency
of Coactivatorsimmunoprecipitation (ChIP) is a powerful technique that
offers the advantage of being able to detect endogenous Although several lines of evidence point to functional
differences between CBP and p300, (reviewed by Glasstranscription factors bound in vivo to promoters under
different physiologic conditions. In addition to direct and Rosenfeld, 2000), evidence for functional differ-
ences among CBP, p300, and pCAF in ERa-mediatedpromoter binding factors, the presence of proteins that
are not bound directly to DNA and that depend on other transcription has been lacking. Our experiments show
Cell
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that p300, CBP and pCAF are all involved in ERa-medi- along with ERa. Finally, CBP and pCAF disassemble
ated gene transcription and that in the first cycle of and the cycle is repeated. It is likely that cell-specific
transcription initiation these three proteins are sequen- factors contribute to selective modulation of ER dynam-
tially recruited to an ERa transcription complex, with ics and cofactor sufficiency in important target tissues
p300 first, followed by CBP and pCAF. These findings other than the breast, including the uterus, skeleton,
agree well with a previous observation that p300 inter- brain, and cardiovascular system.
acts specifically with the nonphosphorylated, initiation-
competent form of RNA polymerase II, whereas pCAF Experimental Procedures
interacts with the elongation-competent, phosphory-
Materials and Reagentslated form (Cho et al., 1998). Our observation that p300
Antibodies used: aERa: Ab-1, Ab-3, and Ab-10 (NeoMarkers, Fre-is not recruited in subsequent cycles is consistent with
mont, CA); aAIB1 (affinity purified rabbit polyclonal serum), aCBPin vitro transcription data suggesting that while p300
(AC26) and ap300 (RW128) (D. M. Livingston, Dana-Farber Cancerplays a role in transcription initiation by ERa, it does not
Institute, Boston, MA); apCAF (Y. Nakatani, Dana-Farber Cancer
participate in reinitiation (Kraus and Kadonaga, 1998). Institute, Boston, MA); aRNA polymerase II: 8WG16 (J. B. Parvin,
These results may also indicate that histone acetylation Brigham and Women’s Hospital, Boston, MA) and H5 (Berkeley Anti-
and chromatin remodeling could be a step-wise process body Company, Richmond, CA); aAcetylated histone (Upstate Bio-
technology, Inc., Lake Placid, NY); aPBP (Atkins et al., 1999); aSMRTin which each of these three cofactors exerts a distinct
(Guenther et al., 2000); aN-CoR (Huang et al., 2000); aVDR (Affinityand nonredundant role and each of these three HAT
BioReagents, Inc., Golden, CO).proteins exhibits a different substrate specificity, as
suggested by in vitro studies (Schiltz et al., 1999).
ChIPThe PBP/DRIP/TRAP complex has been proposed to
Cells were grown to 95% confluence in phenol red-free Dulbecco’srepresent a distinct complex from the ERa-p160 com-
modified Eagle medium (DMEM) supplemented with 10% charcoal-plex and to act at a later stage in gene activation, after
dextran-stripped fetal bovine serum for at least 3 days. Following
histone acetylation by the p160 complex makes chroma- the addition of hormone for various times, cells were washed twice
tin more accessible. Our data show that PBP is recruited with PBS and cross-linked with 1% formaldehyde at room tempera-
to ERa responsive promoters rapidly after estrogen ture for 10 min. Cells then were rinsed with ice-cold PBS twice and
collected into 100 mM Tris-HCl (pH 9.4), 10 mM DTT and incubatedstimulation, at about the same time as p160 factors and
for 15 min at 308C and centrifuged for 5 min at 2000 g. Cells werep300. In addition, our ChIP Re-IP results argue that the
washed sequentially with 1 ml of ice-cold PBS, buffer I (0.25% Tritonp160 complex acts in combination with the PBP com-
X-100, 10 mM EDTA, 0.5 mM EGTA, 10 mM HEPES, pH 6.5), and
plex on the same ERa responsive promoter rather than buffer II (200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 10 mM HEPES,
the two complexes acting independently from each pH 6.5). Cells were then resuspended in 0.3 ml of lysis buffer (1%
other on different promoters. SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, 13 protease inhibitor
cocktail (Roche Molecular Biochemicals, Indianapolis, IN) and soni-The reversed pharmacology of GRIP1 and PBP with
cated three times for 10 s each at the maximum setting (Fisher SonicCoRNR box substitutions allowed us to determine which
Dismembrator, Model 300) followed by centrifugation for 10 min.of these coactivators are sufficient for binding and acti-
Supernatants were collected and diluted in buffer (1% Triton X-100,vation of an ERa complex. Our results indicate that re-
2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.1) followed by
cruitment of a p160 coactivator is sufficient to induce immunoclearing with 2 mg sheared salmon sperm DNA, 20 ml preim-
assembly of an ERa complex capable of gene activation mune serum and protein A-sepharose (45 ml of 50% slurry in 10 mM
without the recruitment of PBP. In contrast recruitment Tris-HCl, pH 8.1, 1 mM EDTA) for 2 hr at 48C. Immunoprecipitation
was performed for 6 hr or overnight at 48C with specific antibodies.of PBP requires both an interaction with ERa and the
After immunoprecipitation, 45 ml protein A-Sepharose and 2 mg ofpresence of the p160 coactivator in the complex. The
salmon sperm DNA were added and the incubation was continuedCoRNR box–substituted p160 factor is not only suffi-
for another 1 hr. Precipitates were washed sequentially for 10 mincient to promote the assembly of an active transcription
each in TSE I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
complex, but was sufficient to reverse the effects of Tris-HCl, pH 8.1, 150 mM NaCl), TSE II (0.1% SDS, 1% Triton X-100,
TAM and promote cell cycle progression in MCF-7 cells. 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl), and buffer III
This supports a pivotal role for p160 coactivators in (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-
HCl, pH 8.1). Precipitates were then washed three times with TEestrogen signaling in breast cancer as suggested by the
buffer and extracted three times with 1% SDS, 0.1 M NaHCO3.amplification of AIB1 in a subset of ER-positive breast
Eluates were pooled and heated at 658C for at least 6 hr to reversecancers.
the formaldehyde cross-linking. DNA fragments were purified withBased on our findings, we propose a dynamic model
a QIAquick Spin Kit (Qiagen, CA). For PCR, 1 ml from a 50 ml DNA
for the cyclic assembly of ERa transcription complexes extraction and 21–25 cycles of amplification were used.
(Figure 7). Rapidly, upon the addition of an agonist such
as E2, liganded-ERa binds DNA. This is almost immedi-
Nuclear Run-on
ately followed by the recruitment of both a HAT-con- MCF-7 cells were grown in estrogen-depleted media for 3 days and
taining p160-p300 complex and the PBP complex. The treated with 100 nM of E2 for various times. Cell nuclei were isolated
p300 HAT complex modifies local chromatin structure with NP-40 lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM
through histone acetylation to facilitate RNA pol II re- MgCl2, and 0.5% [v/v] NP-40) and stored in liquid nitrogen in glycerol
storage buffer (50 mM Tris.HCl, pH 8.3, 40% (v/v) glycerol, 5 mMcruitment. p300 acts in the initial cycle of transcription
MgCl2, and 0.1 mM EDTA). Nuclear run-on transcription was per-initiation, but not in subsequent cycles, perhaps sug-
formed in the presence of 5 ml of 10 mCi/ml [a-32P]UTP. After treat-gesting that histone acetylation by p300 is long lived.
ment of the reaction with RNase-free DNase I and proteinase K,
Concurrent with the onset of transcription, the pol II RNA was extracted with phenol/chloroform/isoamyl alcohol and hy-
C-terminal domain is phosphorylated and CBP replaces bridized to c-Myc and pS2 cDNAs, cathepsin D gene exon 1 DNA
p300 in the complex bringing in pCAF. Subsequently, and b-actin oligo probe (Oncogene Research Products, Cambridge,
MA) immobilized on a nylon membrane.CBP acetylates p160 and leads to the release of p160
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ChIP Re-IP and Real-time PCR and DRIP205, a subunit of the heteromeric DRIP coactivator com-
plex. J. Biol. Chem. 275, 20928–20934.Complexes were eluted from the primary immunoprecipitation by
incubation with 10 mM DTT at 378C for 30 min and diluted 1:50 in Castro-Rivera, E., Wormke, M., and Safe, S. (1999). Estrogen and
buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris- aryl hydrocarbon responsiveness of ECC-1 endometrial cancer
HCl, pH 8.1) followed by reimmunoprecipitation with the second cells. Mol. Cell. Endocrinol. 150, 11–21.
antibodies. ChIP Re-IPs of supernatants were done essentially as
Chakravarti, D., LaMorte, V.J., Nelson, M.C., Nakajima, T., Schulman,
were the primary IPs. For real-time PCR detection of cathepsin D
I.G., Juguilon, H., Montminy, M., and Evans, R.M. (1996). Role of
promoter, the probe and primers were: 6FAM-CCAAGGTTAAATT
CBP/P300 in nuclear receptor signalling. Nature 383, 99–103.
CAAAGTCCCCAGC-TAMRA (probe); TCCAGACATCCTCTCTGGAA
Chen, H., Lin, R.J., Schiltz, R.L., Chakravarti, D., Nash, A., Nagy,(forward primer); GGAGCGGAGGGTCCATTC (reverse primer). The
L., Privalsky, M.L., Nakatani, Y., and Evans, R.M. (1997). NuclearABI PRISM 7700 Sequence Detector and TaqMan 1000 Rxn PCR
receptor coactivator ACTR is a novel histone acetyltransferase andCore Reagents (Perkin Elmer, Branchburg, NJ) and sixty cycles of
forms a multimeric activation complex with P/CAF and CBP/p300.amplification were used.
Cell 90, 569–580.
Chen, H., Lin, R.J., Xie, W., Wilpitz, D., and Evans, R.M. (1999).Construction of CoRNR Box–Containing GRIP1 and PBP
Regulation of hormone-induced histone hyperacetylation and geneCoRNR box–containing GRIP1 (subGRIP1) and PBP (subPBP) were
activation via acetylation of an acetylase. Cell 98, 675–686.constructed by standard molecular techniques. Each of the three
NR boxes in GRIP1 was changed to the CoRNR box sequence Cho, H., Orphanides, G., Sun, X., Yang, X.J., Ogryzko, V., Lees, E.,
-LEDIIRKALMGSFD- and both PBP NR boxes were changed to the Nakatani, Y., and Reinberg, D. (1998). A human RNA polymerase II
chimeric CoRNR box sequence -HRLITLADHIEDIIRKALMG- . complex containing factors that modify chromatin structure. Mol.
Cell. Biol. 18, 5355–5363.
Flow Cytometry Corden, J.L., and Patturajan, M. (1997). A CTD function linking tran-
MCF-7 cells were grown in phenol red-free DMEM supplemented scription to splicing. Trends Biochem. Sci. 22, 413–416.
with 10% charcoal-dextran-stripped fetal bovine serum for 24 hr
de Mercoyrol, L., Job, C., and Job, D. (1989). Studies on the inhibitionand were cotransfected with pcDNA3-GFP and pCMX-GRIP1 or
by alpha-amanitin of single-step addition reactions and productivepcDNA3-subGRIP1. Forty-eight hours after the transfection, cells
RNA synthesis catalysed by wheat-germ RNA polymerase II. Bio-were treated with 100 nM E2 or 5 mM TAM for another 16 hr. Cells
chem. J. 258, 165–169.were then collected and stained with propidium iodide using stan-
Ding, X.F., Anderson, C.M., Ma, H., Hong, H., Uht, R.M., Kushner,dard methods. Cell cycle data were collected with FACScan (Becton
P.J., and Stallcup, M.R. (1998). Nuclear receptor-binding sites ofDickinson Immunocytochemistry System) and analyzed with ModFit
coactivators glucocorticoid receptor interacting protein 1 (GRIP1)LT (Verity Software House, Inc., Topsham, ME).
and steroid receptor coactivator 1 (SRC-1): multiple motifs with
different binding specificities. Mol. Endocrinol. 12, 302–313.Acknowledgments
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